About Gfree Bio
Gfree Bio acquires and develops innovative computational solutions to accelerate drug discovery for small start-ups and emerging biotech companies. We provide our clients complete, cost-effective modeling capabilities as an alternative to costly in-house solutions. Our team and network is comprised of expert scientists with significant drug discovery experience.
We are proud to be a proven corporate partner for academic research labs that are interested in taking new methodology or discovery programs and developing them into commercial ventures (e.g. SBIR/STTR, or new venture).
An interview with Dr. Reynolds – the American Chemical Society (ACS).
Charles H. Reynolds, PhD
Founder, Gfree Bio, LLC
Dr. Reynolds has more than 25 years of experience in drug discovery, and is widely recognized for his expertise in computational chemistry and structure-based drug design. He is currently President of Gfree Bio and an adjunct professor at the Pennsylvania Drug Discovery Institute. Previously, he was Senior Director of Discovery Technologies at Ansaris, where he was responsible for the company’s proprietary fragment-based design technology platform. Prior to joining Ansaris in 2010, he led modeling groups at the Springhouse, PA and La Jolla, CA research sites of Johnson & Johnson. Dr. Reynolds has held a variety of leadership positions in the American Chemical Society (ACS), and was named a Fellow of the ACS in 2010.
Dr. Reynolds received his BA from Austin College and PhD from the University of Texas at Austin. He was an adjunct professor at the University of Pennsylvania and supervised joint graduate and postdoctoral students at the Pennsylvania State University and the University of North Carolina at Chapel Hill. He has published nearly 100 papers, patents, and book chapters, and is a co-editor of two books. His views on drug discovery have been sought by news organizations ranging from C&E News to the Wall Street Journal.Download CV
M. Katharine Holloway, PhD
Principal Scientist, GFree Bio, LLC
During a highly successful 30 year career at Merck, Dr. Holloway provided structure-based design guidance for a wide range of therapeutic targets, particularly in the areas of infectious diseases and neuroscience. She is perhaps best known for the design of protease inhibitors for the treatment of HIV/AIDS (Crixivan™, approved 1996) and Hepatitis C infection (Vanihep™, approved 2014; Zepatier™, approved 2016). She has been honored with several awards as a co-inventor of Crixivan™ including the Intellectual Property Owners National Inventor of the Year Award in 1997, the American Chemical Society Award for Creative Invention in 1999, and the EU Inventor of the Year Award (non-EU country) in 2007. In 2017, she received the American Chemical Society Heroes of Chemistry award recognizing the Merck team who invented Zepatier™, a significant new treatment for chronic Hepatitis C Virus infection. She was also profiled in the 2002 book “Patently Female: From AZT to TV Dinners, Stories of Women Inventors and Their Breakthrough Ideas” by Ethlie Ann Vare and Greg Ptacek and was featured in the 2004 Chemical Heritage Foundation exhibit and website titled “Her Lab in Your Life: Women in Chemistry”.
Kate received a BS in Chemistry and French from the University of Southern Mississippi and a PhD in theoretical Organic Chemistry from The University of Texas at Austin. She is a co-author or co-inventor of ~100 publications and issued patents. She is a former chair of the Computer-Aided Drug Design Gordon Research Conference and the Computers in Chemistry division of the American Chemical Society. She was selected as an American Chemical Society Fellow in 2013, reflecting both scientific excellence as well as long-standing leadership within the organization. She currently serves as a regular member of the AIDS Discovery and Development of Therapeutics (ADDT) NIH study section.LinkedIn Profile Google Scholar Profile